FDAnews
www.fdanews.com/articles/102280-vivus-begins-third-qnexa-trial

Vivus Begins Third Qnexa Trial

December 14, 2007

Vivus has started a third Phase III study of Qnexa in obese patients with co-morbidities.

The randomized, double-blind, placebo-controlled, seven-arm, prospective EQUATE study will enroll 700 patients with body mass indexes of 30–45.

Patients will undergo a four-week dose escalation period followed by 24 weeks of treatment. Subjects will receive once-a-day treatment with mid-dose Qnexa (7.5 mg phentermine/46 mg topiramate), full-strength Qnexa (15 mg phentermine/92 mg topiramate), the respective phentermine and topiramate constituents or placebo, Vivus said.